Skip to content
OpenCapital
Get started

Eli Lilly LLY Oncology — Revenue

Other product segments

Mounjaro
$8.66B+125%
Zepbound
$4.16B+79.9%
Verzenio
$1.3B+12.3%
Jardiance
$1.11B+9.9%
Other oncology
$966M+22.4%
Trulicity
$919M-16.1%
Other cardiometabolic health
$905M-4.2%
Taltz
$733M-3.8%
Other immunology
$470M+44.2%
Neuroscience
$382M+40.4%

Similar metrics at other companies

BillionToOne, Inc. logo
BLLNOncology — Revenue
$10.72M+392%
Jazz Pharmaceuticals logo
JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax
$333.4M+45.3%
Lantheus Holdings logo
LNTHOncology — Revenue
$240.92M-6.5%
Natera, Inc. logo
NTRAOncology — Revenue recognized
$100K0.0%
Guardant Health logo
GHOncology — Total Revenue
$204.95M+36.1%
Pfizer logo
PFEAll other Oncology — Revenues:
$376M-0.3%

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.09T+56.4%
Enterprise value$1.12T+53.8%
P/E42.9×-7.3×
P/S15×+2.0×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's oncology — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's oncology — revenue?
Eli Lilly (LLY) reported oncology — revenue of $2.27B in Q1 2026.
How has Eli Lilly's oncology — revenue changed year-over-year?
Eli Lilly's oncology — revenue increased by 16.4% year-over-year, from $1.95B to $2.27B.
What is the long-term trend for Eli Lilly's oncology — revenue?
Over 4 years (2021 to 2025), Eli Lilly's oncology — revenue has grown at a 13.0% compound annual growth rate (CAGR), from $5.74B to $9.38B.
What does oncology — revenue mean?
This metric measures the net revenue recognized from sales of oncology-related pharmaceutical products to unaffiliated third-party customers. It excludes intercompany transactions to provide a clear view of the segment's external commercial performance. This is a primary measure of the economic value generated by the company's oncology business unit.